Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Multi-Center, Long-Term Extension Study Investigating the Efficacy and Safety of Abrocitinib, With or Without Topical Medications, Administered to Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis.’ The study aims to evaluate the efficacy and safety of Abrocitinib, an oral medication, in treating moderate to severe atopic dermatitis in patients aged 12 and older. This research is significant as it addresses a common and challenging skin condition, potentially offering a new treatment option.
The intervention being tested is Abrocitinib, available in 100 mg and 200 mg dosages, administered orally once daily. The study also includes a sub-study to assess the drug’s impact on adolescent bone health using MRI scans.
The study design is interventional with a randomized, parallel assignment. It employs quadruple masking, meaning the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on March 8, 2018, with a primary completion date yet to be reached. The last update was submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might influence market dynamics.
This study update could positively impact Pfizer’s stock performance by enhancing investor confidence in the company’s dermatology portfolio. As Abrocitinib progresses through clinical trials, it may strengthen Pfizer’s competitive position in the dermatology market, potentially affecting investor sentiment and market share.
The study is ongoing, with further details available on the ClinicalTrials portal.